ATE130327T1 - Polyethylenglykolderivate, modifizierte peptide derselben, ihre herstellung sowie verwendung der modifizierten peptide. - Google Patents

Polyethylenglykolderivate, modifizierte peptide derselben, ihre herstellung sowie verwendung der modifizierten peptide.

Info

Publication number
ATE130327T1
ATE130327T1 AT91114221T AT91114221T ATE130327T1 AT E130327 T1 ATE130327 T1 AT E130327T1 AT 91114221 T AT91114221 T AT 91114221T AT 91114221 T AT91114221 T AT 91114221T AT E130327 T1 ATE130327 T1 AT E130327T1
Authority
AT
Austria
Prior art keywords
polyethylene glycol
modified peptides
glycol derivatives
same
peptides
Prior art date
Application number
AT91114221T
Other languages
English (en)
Inventor
Yoshiharu Ikeda
Yoshiyuki Kai
Keiichi Ono
Original Assignee
Sumitomo Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma filed Critical Sumitomo Pharma
Application granted granted Critical
Publication of ATE130327T1 publication Critical patent/ATE130327T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C08G65/3324—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof cyclic
    • C08G65/3326—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof cyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/3311—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group
    • C08G65/3314—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group cyclic
    • C08G65/3315—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group cyclic aromatic
    • C08G65/3317—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group cyclic aromatic phenolic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyethers (AREA)
  • Medicinal Preparation (AREA)
AT91114221T 1990-08-28 1991-08-24 Polyethylenglykolderivate, modifizierte peptide derselben, ihre herstellung sowie verwendung der modifizierten peptide. ATE130327T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2227541A JP3051145B2 (ja) 1990-08-28 1990-08-28 新規なポリエチレングリコール誘導体修飾ペプチド

Publications (1)

Publication Number Publication Date
ATE130327T1 true ATE130327T1 (de) 1995-12-15

Family

ID=16862521

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91114221T ATE130327T1 (de) 1990-08-28 1991-08-24 Polyethylenglykolderivate, modifizierte peptide derselben, ihre herstellung sowie verwendung der modifizierten peptide.

Country Status (9)

Country Link
US (1) US5183660A (de)
EP (1) EP0473084B1 (de)
JP (1) JP3051145B2 (de)
AT (1) ATE130327T1 (de)
CA (1) CA2050063A1 (de)
DE (1) DE69114614T2 (de)
DK (1) DK0473084T3 (de)
ES (1) ES2079534T3 (de)
GR (1) GR3018612T3 (de)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951972A (en) * 1990-05-04 1999-09-14 American Cyanamid Company Stabilization of somatotropins and other proteins by modification of cysteine residues
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
WO1993012145A1 (en) * 1991-12-19 1993-06-24 Baylor College Of Medicine Pva or peg conjugates of peptides for epitope-specific immunosuppression
US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
ES2095086T3 (es) * 1992-10-29 1997-02-01 Genentech Inc Metodo para el tratamiento y la prevencion de la obesidad.
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) * 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US6015897A (en) * 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
US5550212A (en) * 1993-12-17 1996-08-27 The Administrators Of The Tulane Educational Fund Analogues of hGH-RH(1-29)NH2 having antagonistic activity
US5441544A (en) * 1993-12-23 1995-08-15 Chevron Chemical Company Fuel compositions containing substituted poly(oxyalkylene) aromatic ethers
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US6172045B1 (en) 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
US6908903B1 (en) 1994-12-07 2005-06-21 Aletheon Pharmaceuticals, Inc. Cluster clearing agents
JP3708151B2 (ja) * 1994-12-15 2005-10-19 協和醗酵工業株式会社 Ｐｅｇ化したヒト顆粒球コロニー刺激因子の定量法
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
ATE257844T1 (de) * 1995-03-10 2004-01-15 Nakamura Toshikazu Menschlicher wachstumsfaktor (hgf), verändert durch polyethylenglykol
DE19514087A1 (de) * 1995-04-13 1996-10-17 Deutsches Krebsforsch Konjugat aus einem Wirkstoff, einem Polyether und ggfs. einem nicht als körperfremd angesehenen, nativen Protein
US5756593A (en) * 1995-05-15 1998-05-26 Enzon, Inc. Method of preparing polyalkyene oxide carboxylic acids
EP0922446A1 (de) * 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Lösungsphase Verfahrung zur ortspezifischer Herstellung von GRF-PEG Konjugaten
US6066673A (en) * 1998-03-12 2000-05-23 The Procter & Gamble Company Enzyme inhibitors
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6251382B1 (en) 1998-04-17 2001-06-26 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
CA2395254C (en) * 1999-12-24 2010-05-11 Kyowa Hakko Kogyo Co., Ltd. Branched polyalkylene glycols
MXPA03007392A (es) * 2001-02-20 2003-12-04 Enzon Inc Enlazantes polimericos ramificados terminalmente y conjugados polimericos que contienen los mismos.
CA2447236A1 (en) 2001-05-21 2002-11-28 Nektar Therapeutics Pulmonary administration of chemically modified insulin
DE60223047T2 (de) 2001-08-22 2008-07-24 Bioartificial Gel Technologies Inc., Montreal Verfahren zur herstellung von aktivierten polyethylenglykolen
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
PA8588901A1 (es) * 2002-11-20 2005-02-04 Pharmacia Corp Conjugados de hormona de crecimiento humana pegilados n-terminales y proceso para su preparacion
CN102319437B (zh) * 2002-12-26 2017-10-13 山景医药公司 具有增强的生物学效用的干扰素‑β的聚合物缀合物
AU2003303636B2 (en) * 2002-12-26 2010-08-05 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
JP4369194B2 (ja) * 2003-09-30 2009-11-18 Ｈｏｙａ株式会社 プラスチックレンズ及びその製造方法
WO2005056764A2 (en) 2003-12-05 2005-06-23 Compound Therapeutics, Inc. Inhibitors of type 2 vascular endothelial growth factor receptors
AU2005319099B2 (en) * 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
CN103755800B (zh) * 2004-02-02 2016-02-24 Ambrx公司 经修饰的人类生长激素多肽与其用途
US7351787B2 (en) * 2004-03-05 2008-04-01 Bioartificial Gel Technologies, Inc. Process for the preparation of activated polyethylene glycols
WO2005107815A2 (en) * 2004-05-03 2005-11-17 Nektar Therapeutics Al, Corporation Polymer derivatives comprising an imide branching point
CA2581423A1 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
EP3061461A1 (de) 2004-10-29 2016-08-31 ratiopharm GmbH Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf)
AU2005323106B2 (en) 2004-12-22 2010-07-29 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
EP1674113A1 (de) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Konjugate von insulinähnlichem Wachstumfaktor-1 und Poly(Ethylenglykol)
KR101224781B1 (ko) * 2004-12-22 2013-01-21 암브룩스, 인코포레이티드 비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
DE602005015817D1 (de) * 2005-01-25 2009-09-17 Varian B V Chromatographische Säulen
EP1871795A4 (de) 2005-04-08 2010-03-31 Biogenerix Ag Zusammensetzungen und verfahren zur herstellung von glycosylierungsmutanten eines proteaseresistenten menschlichen wachstumshormons
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
PT2279758E (pt) 2005-06-16 2015-05-27 Nektar Therapeutics Conjugados possuindo uma ligação degradável e reagentes poliméricos úteis na preparação de tais conjugados
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
US7989554B2 (en) * 2006-01-10 2011-08-02 Enzon Pharmaceuticals, Inc. Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
CN101484469B (zh) 2006-08-31 2012-12-12 弗·哈夫曼-拉罗切有限公司 生产胰岛素样生长因子-ⅰ的方法
BRPI0717505B8 (pt) 2006-10-04 2021-05-25 Novo Nordisk As conjugado de peptídeo e formulação farmacêutica
AR063384A1 (es) 2006-10-25 2009-01-28 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
JP5537946B2 (ja) 2006-11-22 2014-07-02 ブリストル−マイヤーズ スクイブ カンパニー Ｉｇｆ−ｉｒを含むチロシンキナーゼ受容体に対する改変タンパク質に基づく標的治療薬
WO2008095182A2 (en) * 2007-02-01 2008-08-07 National Research Council Of Canada Formulations of lipophilic bioactive molecules
US20100144599A1 (en) 2007-02-02 2010-06-10 Bristol-Myers Squibb Company Vegf pathway blockade
EP2738257A1 (de) 2007-05-22 2014-06-04 Amgen Inc. Zusammensetzungen und Verfahren zur Herstellung bioaktiver Fusionsproteine
CL2008002054A1 (es) * 2007-07-17 2009-05-29 Hoffmann La Roche Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
CL2008002053A1 (es) * 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
PE20091931A1 (es) 2008-05-22 2009-12-31 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
US8067201B2 (en) 2009-04-17 2011-11-29 Bristol-Myers Squibb Company Methods for protein refolding
LT2440239T (lt) 2009-06-09 2017-12-11 Prolong Pharmaceuticals, LLC Hemoglobino kompozicijos
US9587006B2 (en) 2010-02-11 2017-03-07 Hoffmann-La Roche Inc. IGF-I poly (ethylene glycol) conjugates
US9562089B2 (en) 2010-05-26 2017-02-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
RU2566267C2 (ru) 2010-09-14 2015-10-20 Ф. Хоффманн-Ля Рош Аг Способ очистки пегилированного эритропоэтина
US9340590B2 (en) 2011-03-16 2016-05-17 Amgen Inc. Potent and selective inhibitors of NaV1.3 and NaV1.7
US20140187488A1 (en) 2011-05-17 2014-07-03 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
JP2015504038A (ja) 2011-10-31 2015-02-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 低減した免疫原性を有するフィブロネクチン結合ドメイン
WO2013138338A2 (en) 2012-03-12 2013-09-19 Massachusetts Institute Of Technology Methods for treating tissue damage associated with ischemia with apoliporotein d
WO2013149219A2 (en) 2012-03-30 2013-10-03 Sorrento Therapeutics Inc. Fully human antibodies that bind to vegfr2
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
AU2013267161A1 (en) 2012-05-31 2014-11-20 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
JP6429771B2 (ja) 2012-06-21 2018-11-28 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ｃ−Ｍｅｔに結合する抗原結合タンパク質
WO2013192596A2 (en) 2012-06-22 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind ccr2
HUE043482T2 (hu) 2012-09-13 2019-08-28 Bristol Myers Squibb Co Miosztatint megkötõ fibronektin alapú váz domén proteinek
JP6426107B2 (ja) 2012-12-20 2018-11-21 アムジエン・インコーポレーテツド Ａｐｊ受容体アゴニストおよびその使用
WO2014120891A2 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
EP3155002B1 (de) 2014-06-10 2019-11-27 Amgen Inc. Apelin polypeptides
WO2016025647A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
WO2016025642A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
EP3183000A4 (de) 2014-08-22 2018-04-25 Sorrento Therapeutics, Inc. Antigenbindende proteine zur bindung von cxcr3
US11229713B2 (en) 2014-11-25 2022-01-25 Bristol-Myers Squibb Company Methods and compositions for 18F-radiolabeling of biologics
WO2016086021A1 (en) 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Novel pd-l1 binding polypeptides for imaging
CN108271359B (zh) 2015-02-13 2021-11-09 索伦托药业有限公司 结合ctla4的抗体治疗剂
CN113527495A (zh) 2015-04-08 2021-10-22 索伦托药业有限公司 与cd38结合的抗体治疗剂
CR20170482A (es) 2015-04-24 2018-03-07 Viiv Healthcare Uk No 5 Ltd Polipéptidos dirigidos a la fusión de vih
EP3353198B1 (de) 2015-09-23 2020-06-17 Bristol-Myers Squibb Company Glypican-3-bindende fibronektin-basierte gerüstmoleküle
KR102927822B1 (ko) 2016-01-29 2026-02-13 주식회사유한양행 Pd-l1에 결합하는 항원 결합 단백질
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
AU2017295037B2 (en) 2016-07-15 2021-07-22 F. Hoffmann-La Roche Ag Method for purifying PEGylated erythropoietin
US11485781B2 (en) 2017-08-17 2022-11-01 Massachusetts Institute Of Technology Multiple specificity binders of CXC chemokines
HRP20220388T1 (hr) 2017-12-29 2022-05-27 F. Hoffmann - La Roche Ag Postupak za dobivanje pegiliranog proteinskog pripravka
JP7410860B2 (ja) 2017-12-29 2024-01-10 エフ． ホフマン－ラ ロシュ アーゲー Ｐｅｇ化タンパク質組成物を提供するための方法
JP7137625B2 (ja) 2017-12-29 2022-09-14 エフ．ホフマン－ラ ロシュ アーゲー Ｐｅｇ化タンパク質組成物を提供するための方法
AU2019346335B2 (en) 2018-09-28 2024-07-25 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
WO2020154032A1 (en) 2019-01-23 2020-07-30 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
MX2022006787A (es) 2019-12-05 2022-07-19 Sorrento Therapeutics Inc Composiciones y metodos que comprenden un anticuerpo anti-cd47 en combinacion con un anticuerpo dirigido al tumor.
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
CN115485300A (zh) 2020-02-26 2022-12-16 索伦托药业有限公司 具有通用掩蔽部分的可活化的抗原结合蛋白
EP4110407A1 (de) 2020-02-28 2023-01-04 Bristol-Myers Squibb Company Radioaktiv markierte fibronectinbasierte gerüste und antikörper sowie therapeutische verwendungen davon
WO2021195089A1 (en) 2020-03-23 2021-09-30 Sorrento Therapeutics, Inc. Fc-coronavirus antigen fusion proteins, and nucleic acids, vectors, compositions and methods of use thereof
US11673930B2 (en) 2020-05-12 2023-06-13 Regeneran Pharmaceuticals, Inc. IL10 agonists and methods of use thereof
US11241410B2 (en) * 2020-05-18 2022-02-08 Amanuel Tesfazion Method and compound for the treatment of covid-19
WO2021263166A1 (en) 2020-06-26 2021-12-30 Sorrento Therapeutics, Inc. Anti-pd1 antibodies and uses thereof
KR20240046251A (ko) 2021-08-16 2024-04-08 리제너론 파아마슈티컬스, 인크. 신규 il27 수용체 효능제 및 그의 사용 방법
JP2024544534A (ja) 2021-11-11 2024-12-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃｄ２０－ｐｄ１結合分子及びその使用方法
EP4709756A1 (de) 2023-05-10 2026-03-18 Regeneron Pharmaceuticals, Inc. Cd20-pd1-bindende moleküle und verfahren zur verwendung davon
WO2025006676A2 (en) 2023-06-27 2025-01-02 Firecyte Therapeutics, Inc. Insulin-like growth factor binding protein like 1 (igfbpl1) compositions and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE32439B1 (en) * 1967-09-27 1973-08-08 Madan Ag Substituted phenylacetic acids and process of preparation thereof
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2962737D1 (en) * 1978-11-14 1982-06-24 Sagami Chem Res Process for the preparation of aromatically substituted acetic acids
DE3125059A1 (de) * 1981-06-26 1983-01-05 Bayer Ag, 5090 Leverkusen Dioxybenzoletherderivate, diese enthaltende arzneimittel, verfahren zu ihrer herstellung und ihre verwendung
EP0154316B1 (de) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemisch modifizierte Lymphokine und Verfahren zu ihrer Herstellung
JPS6142558A (ja) * 1984-08-06 1986-03-01 Matsushita Electric Works Ltd アミノ樹脂成形材料
ES8800982A1 (es) * 1985-07-05 1987-12-01 Takeda Chemical Industries Ltd Un metodo para producir la enzima superoxido-dismutasa modificada con derivados de polietilenglicol y triazina.
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
JPS63146791A (ja) * 1986-12-08 1988-06-18 Hitachi Ltd 酵素の固定化方法
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
IT1216473B (it) * 1988-02-29 1990-03-08 Montefibre Spa Derivati poliossialchilen_etere_terminati di acidi organici, loro esteri alchilici e loro sali alcalini e alcalino terrosi.
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
JP2958019B2 (ja) * 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
JP2997004B2 (ja) * 1989-05-26 2000-01-11 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法

Also Published As

Publication number Publication date
ES2079534T3 (es) 1996-01-16
DK0473084T3 (da) 1996-03-04
GR3018612T3 (en) 1996-04-30
EP0473084A2 (de) 1992-03-04
EP0473084B1 (de) 1995-11-15
CA2050063A1 (en) 1992-03-01
EP0473084A3 (en) 1992-04-29
JP3051145B2 (ja) 2000-06-12
JPH04108827A (ja) 1992-04-09
US5183660A (en) 1993-02-02
DE69114614T2 (de) 1996-03-28
DE69114614D1 (de) 1995-12-21

Similar Documents

Publication Publication Date Title
DE69114614D1 (de) Polyethylenglykolderivate, modifizierte Peptide derselben, ihre Herstellung sowie Verwendung der modifizierten Peptide.
EP0340741A3 (de) Polyäthylenglykolderivate, modifizierte Peptide und ihre Herstellung
DE3883016D1 (de) Komplexe verbindungen aus bioflavonoiden mit phospholipiden, ihre herstellung und verwendung und sie enthaltende pharmazeutische und kosmetische zusammensetzungen.
DE59010536D1 (de) Diphenylheteroalkylderivate, ihre Herstellung und daraus hergestellte Arzneimittel und Kosmetika
DE69112989D1 (de) Aminocoumaranderivate, ihre Herstellung und Verwendung.
ATE235459T1 (de) Derivate von aminosäuren, sie enthaltende pharmazeutische zusammensetzungen sowie deren herstellunsgverfahren
DE69817802D1 (de) Substituierte phenylderivate, ihre herstellung und verwendung
ATE179706T1 (de) N-heteroaryl-n'-phenylharnstoffderivate, ihre herstellung und verwendung
FI96309B (fi) Menetelmä farmakologisesti arvokkaiden fuusioituneiden polysyklisten yhdisteiden valmistamiseksi
DE69407322D1 (de) Aufklärung und Synthese von ausgewählten Pentapeptiden
FI920023A0 (fi) Heteroarylpiperazinfoereningar som antipsykotiska aemnen.
DE69312232D1 (de) Bpc-peptide, ihre herstellung und verwendung
EP0400486A3 (de) Polyethylenglycolderivate, modifizierte Peptide und ihre Herstellung
ATE140227T1 (de) 2-saccharinylmethyl-aryl-carboxylate-derivate als proteolytic enzym-inhibitore und zusammensetzungen davon und behandlungsmethoden darauf
ATE80613T1 (de) Verwendung von spergualinderivaten zur herstellung von arzneimitteln mit immunodepressiver wirkung.
DE59203924D1 (de) Substituierte Aminosäureamid-Derivate deren Herstellung und Verwendung als Fungizide.
DE69224613D1 (de) Peptide, Herstellung und deren Verwendung
DE69130266D1 (de) Optisch wirksame Alkylendioxybenzolderivate und ihre Verwendung als Arzneimittel
DE68922035D1 (de) Glyzerin-Derivat und dessen pharmazeutische Verwendung.
ATE125270T1 (de) Tert-butyloxycarbonyl-l-tyrosyl- peptidoglycanmonomer und deren 125 i-markiertes derivat, deren herstellung und verwendung.
ATE88176T1 (de) 2-hydroxy-3-aryloxy-propylaminderivate mit kardiovaskulaerer wirkung.
DE69511449D1 (de) Octahydro-2-Naphthalincarbonsäure-Derivate, ihre Herstellung und Verwendung
ATE186214T1 (de) Verwendung von rosmanolderivaten zur herstellung von antiradikalischen und/oder antilipoperoxidativen und/oder hepatotropen arzneistoffen
ATE97130T1 (de) 13-brom und 13, 14-dibrom-ergoline, ihre herstellung und verwendung in arzneimitteln.
ITMI920082A1 (it) Derivati solforati di acidi biliari

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee